By DOROTHY CHISI –
THE National Biosafety Authority (NBA) has approved another HIV vaccine clinical trial for the prevention of HIV-1 infection in women.
NBA chief executive officer Luckson Tonga said the phase-two trial, which will involve about 500 participants would be conducted in Lusaka and Ndola by the Centre for Infectious Disease Research in Zambia (CIDRZ) and the Zambia Emory HIV Research Project (ZEHRP).
He said the authority approved one research trial last year involving an HIV vaccine by CIDRZ on the safety and immunogenicity of HVTN 120/ALVAC which was being conducted in Lusaka. Read more